Welcome to our dedicated page for Mersana Therapeutics SEC filings (Ticker: MRSN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 250-page biotech filing packed with pharmacology terms, trial endpoints, and collaboration clauses can slow any analysis. Mersana Therapeutics SEC documents layer complex antibody-drug conjugate science on top of detailed R&D accounting—an ideal recipe for missed insights.
Stock Titan fixes that friction. Our AI-powered summaries translate every Mersana Therapeutics annual report 10-K simplified section, spotlighting Fleximer platform updates, cash runway disclosures, and key risk factors. Need the latest Mersana Therapeutics quarterly earnings report 10-Q filing? We post it the moment EDGAR releases, then surface revenue from partnerships, clinical-trial spend by program, and any changes to liquidity outlook—no manual page-flipping required.
Looking for insider sentiment? Receive real-time alerts whenever a director files Mersana Therapeutics insider trading Form 4 transactions. Our dashboard groups Mersana Therapeutics executive stock transactions Form 4 by buyer, price, and trial milestone so you can track conviction without spreadsheets.
- Rapid AI notes that flag 8-K material event triggers—perfect for "Mersana Therapeutics 8-K material events explained" searches.
- Side-by-side redline of sequential 10-Qs to answer "Mersana Therapeutics earnings report filing analysis."
- One-click access to the definitive proxy for "Mersana Therapeutics proxy statement executive compensation."
Whether you’re understanding Mersana Therapeutics SEC documents with AI for a quick model update or deep-diving into drug-candidate economics, Stock Titan delivers every filing type�10-K, 10-Q, 8-K, S-3, Form 4—along with plain-English context. Spend minutes, not evenings, turning dense ADC disclosures into actionable decisions.
Mersana Therapeutics, Inc. (MRSN) has filed an 8-K disclosing that it will implement a 1-for-25 reverse stock split, effective 5:00 p.m. ET on 25 Jul 2025. Each block of 25 outstanding common shares will be reclassified into one share; fractional shares will be cashed out. The maneuver does not alter the company’s authorized share count or par value, but all equity incentive plan share pools and outstanding awards will be proportionally adjusted.
The reverse split is intended to restore compliance with Nasdaq’s $1.00 minimum bid price requirement, which the company previously flagged in its 2025 proxy. Post-split trading will commence on 28 Jul 2025 under the existing ticker “MRSN� with a new CUSIP of 59045L205.
No other material events, financial results or changes in fiscal year were reported. A copy of the Certificate of Amendment is attached as Exhibit 3.1.
Mersana Therapeutics, Inc. (NASDAQ: MRSN) filed an 8-K to disclose the termination of its October 29, 2021 loan and security agreement with Oxford Finance LLC and other lenders. On July 1, 2025, the company paid approximately $17.9 million, which fully satisfied and discharged all outstanding indebtedness and related obligations under the agreement. As a result, the loan agreement and its related collateral security documents are no longer in effect.
The disclosure was made under Item 1.02 (“Termination of a Material Definitive Agreement�). No other material events, financial results, or operational updates were included in this filing.
FAQ
What is the current stock price of Mersana Therapeutics (MRSN)?
What is the market cap of Mersana Therapeutics (MRSN)?
What is the primary focus of Mersana Therapeutics?
How does the Fleximer platform benefit their ADC development?
What are the two core ADC platforms used by Mersana?
What therapeutic areas does Mersana target?
How does Mersana differentiate itself in the ADC market?
What role do strategic collaborations play in Mersana's business model?
How does Mersana ensure clinical excellence in its therapies?
What are some common industry keywords associated with Mersana?
